Evotec SE (EVO) Non-Current Deffered Revenue (2020 - 2025)

Evotec SE (EVO) reported Non-Current Deffered Revenue of $169.2 million for Q4 2025, up 1.04% on a YoY basis from $167.4 million in Q4 2024, and up 1.04% sequentially from $167.4 million in Q4 2024.

Evotec SE (EVO) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends

Evotec SE (EVO) has 6 years of Non-Current Deffered Revenue data on file, last reported at $169.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 1.04% year-over-year to $169.2 million; the trailing twelve-month figure through Dec 2025 stood at $169.2 million (up 1.04% YoY), and the FY2025 full-year result was $169.2 million, up 1.04% from the prior year.
  • Non-Current Deffered Revenue improved to $169.2 million in Q4 2025, from $167.4 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $210.3 million in Q4 2022 to a low of -$205795.8 in Q2 2022.
  • A 5-year average of $125.3 million and a median of $167.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
  • Across the five-year window, Non-Current Deffered Revenue surged 449.18% in 2022 and dropped 20.56% in 2023, its largest moves.
  • Tracing EVO's Non-Current Deffered Revenue over 5 years: stood at $38.3 million in 2021, then surged by 449.18% to $210.3 million in 2022, then declined by 20.56% to $167.1 million in 2023, then increased by 0.21% to $167.4 million in 2024, then climbed by 1.04% to $169.2 million in 2025.
  • Business Quant data shows EVO's Non-Current Deffered Revenue at $169.2 million in Q4 2025, $167.4 million in Q4 2024, and $167.1 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Evotec SE 351.60 Mn 351.08 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 169.16 Mn
Dec 31, 2024 167.43 Mn
Dec 31, 2023 167.08 Mn
Dec 31, 2022 210.31 Mn
Jun 30, 2022 -205,795.75
Dec 31, 2021 38.30 Mn
Dec 31, 2020 26.75 Mn